Analyst Rating Update on Medtronic plc (MDT)

Medtronic plc (MDT) : The consensus on Medtronic plc (MDT) based on 20 analyst recommendation on the company stock is 1.78, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Medtronic plc (MDT) : The most positive equity analysts on Medtronic plc (MDT) expects the shares to touch $104, whereas, the least positive believes that the stock will trade at $56 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $89.54 with an expected fluctuation of $11.5 from the mean.

For the current week, the company shares have a recommendation consensus of Buy. Also, SunTrust Robinson Humphrey maintains its rating on Medtronic plc (NYSE:MDT). The global brokerage major raises the current price target from $93 per share to $98 per share. Analysts at the SunTrust Robinson Humphrey have a current rating of Buy on the shares. The rating by the firm was issued on June 13, 2016.


Medtronic plc (NYSE:MDT): The stock opened at $87.57 on Wednesday but the bulls could not build on the opening and the stock topped out at $87.62 for the day. The stock traded down to $86.46 during the day, due to lack of any buying support eventually closed down at $86.67 with a loss of -1.11% for the day. The stock had closed at $87.64 on the previous day. The total traded volume was 3,966,387 shares.

Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.